INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 35 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2014. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2017 | $5,850,000 | +7.7% | 360,000 | 0.0% | 2.31% | +54.5% |
| Q4 2016 | $5,432,000 | -47.2% | 360,000 | -46.7% | 1.50% | -36.9% |
| Q3 2016 | $10,286,000 | -60.7% | 675,000 | 0.0% | 2.37% | -68.1% |
| Q2 2016 | $26,203,000 | +39.6% | 675,000 | 0.0% | 7.44% | +79.9% |
| Q1 2016 | $18,764,000 | -48.3% | 675,000 | 0.0% | 4.14% | -41.4% |
| Q4 2015 | $36,308,000 | +41.7% | 675,000 | +5.5% | 7.06% | +11.5% |
| Q3 2015 | $25,626,000 | +122.8% | 640,000 | +77.8% | 6.33% | +139.1% |
| Q2 2015 | $11,502,000 | +33.8% | 360,000 | 0.0% | 2.65% | +46.0% |
| Q1 2015 | $8,597,000 | +35.3% | 360,000 | 0.0% | 1.81% | -19.4% |
| Q4 2014 | $6,354,000 | +28.7% | 360,000 | 0.0% | 2.25% | +18.0% |
| Q3 2014 | $4,936,000 | +36.1% | 360,000 | +67.3% | 1.91% | +54.5% |
| Q2 2014 | $3,628,000 | +57.5% | 215,202 | +69.9% | 1.23% | +55.6% |
| Q1 2014 | $2,303,000 | – | 126,695 | – | 0.79% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 360,000 | $11,502,000 | 2.65% |
| Redmile Group, LLC | 610,171 | $19,495,000 | 1.60% |
| Pier Capital, LLC | 257,256 | $8,219,000 | 1.18% |
| WALL STREET ASSOCIATES | 358,857 | $11,465,000 | 1.08% |
| SENZAR ASSET MANAGEMENT, LLC | 161,300 | $5,154,000 | 0.88% |
| Rhenman & Partners Asset Management AB | 206,000 | $6,582,000 | 0.79% |
| EAM Investors, LLC | 152,389 | $4,869,000 | 0.57% |
| EDMOND DE ROTHSCHILD (SUISSE) S.A. | 50,000 | $1,598,000 | 0.51% |
| Visium Asset Management, LP | 1,051,479 | $33,595,000 | 0.48% |
| SPHERA FUNDS MANAGEMENT LTD. | 128,000 | $4,090,000 | 0.40% |